Equillium Inc
USUSDEquillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- equilliumbio.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- LA JOLLA, United States
- Tegevjuht
- Bruce Steel
- Töötajad
- 14
- Ringluses Olevad Aktsiad
- 63.41 mln seisuga 2026-08-07
- Vabalt Kaubeldavad Aktsiad
- 36.97 mln
- Turukapitalisatsioon
- 89.41 mln USD
- Siseringi Isikud
- 16%
- Institutsionaalsed Investorid
- 65.76%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- P/E
- kahjum
- FCF
- −20.1 mln USD
- Võlg
- 7.64 mln USDnetoraha
- Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
- NAV
Kirjeldus
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| Jupiter Topco LLC | 10.24% | 6.49 mln | 2026-06-30 |
| Decheng Capital LLC | 7.01% | 4.45 mln | 2026-06-30 |
| Affinity Asset Advisors,… | 6.47% | 4.1 mln | 2026-06-30 |
| Adar1 Capital Management… | 5.93% | 3.76 mln | 2026-06-30 |
| Aberdeen Group plc | 5.73% | 3.63 mln | 2026-06-30 |
| abrdn Life Sciences Inve… | 5.73% | 3.63 mln | 2026-06-30 |
| Woodline Partners LP | 5.52% | 3.5 mln | 2026-06-30 |
| RA Capital Management, L… | 4.88% | 3.1 mln | 2026-06-30 |
| Stempoint Capital LP | 3.18% | 2.02 mln | 2026-06-30 |
| Vanguard Capital Managem… | 2.87% | 1.82 mln | 2026-06-30 |
| Eversept Partners, LP | 2.4% | 1.52 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.21% | 1.4 mln | 2026-06-30 |
| CONNELLY STEPHEN (Presid… | ≈1.2% | 762 025 | 2026-06-05 |
| VANGUARD INDEX FUNDS-Van… | 0.54% | 344 489 | 2026-06-30 |
| Fidelity Concord Street… | 0.26% | 162 851 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.24% | 153 076 | 2026-08-31 |
| American Century ETF Tru… | 0.12% | 75 411 | 2026-08-31 |
| ZEDELMAYER CHRISTINE (Ch… | ≈0.1% | 62 586 | 2026-06-05 |
| Fidelity Concord Street… | 0.09% | 54 677 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 47 465 | 2026-07-31 |
| Invesco Exch-Trd Fd. TRT… | 0.06% | 38 516 | 2026-08-31 |
| Fidelity Concord Street… | 0.06% | 36 683 | 2026-07-31 |
| TOM PENNY (Officer) | — | 0 | 2026-05-28 |
| KEYES JASON A (Chief Fin… | — | — | 2025-01-23 |
Logi Sisse Google